Romiplostim (Nplate, Amgen), a synthetic protein that binds to and stimulates the thrombopoietin receptor, induced a rapid platelet response in most adult patients with immune thrombocytopenia (ITP) who had low platelet counts or bleeding symptoms, regardless of splenectomy status.
Romiplostim (Nplate, Amgen), a synthetic protein that binds to and stimulates the thrombopoietin receptor, induced a rapid platelet response in most adult patients with immune thrombocytopenia (ITP) who had low platelet counts or bleeding symptoms, regardless of splenectomy status.
The drug also maintained a consistent safety profile, according to data from an international, phase 3, open-label, single-arm, prospective study presented December 13 at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego.
"These are the final results from the largest prospective study of the safety and efficacy of Nplate in adult patients with ITP to date," Susie Jun, MD, PhD, Amgen's global development lead for Nplate, told Formulary. "This data, along with findings reported from previous studies, confirm Nplate's ability to successfully treat these patients."
The primary study objective was incidence of adverse events and antibody formation. Secondary study objectives aimed at evaluating platelet responses defined as either (1) doubling of baseline count and a platelet count greater than or equal to 50,000 platelets/μL or (2) a platelet count increase greater than or equal to 20,000 platelets/μL from baseline. Results were reported by lead investigator, Ann Janssens of the Department of Hematology, University Hospitals Leuven, Belgium.
Patients enrolled in the study received romiplostim once weekly, with dose adjustments to maintain platelet counts of greater than or equal to 50,000 platelets/μL. Forty-one percent (168/407) of patients initiated romiplostim at a starting dose of 3 μg/kg/wk; 59% (239/407) initiated romiplostim at a starting dose of 1 μg/kg/wk. Median treatment duration was 44.29 weeks. Fifty-one percent of patients had previously undergone splenectomy.
Of the 71% of patients (288/407) who completed the study, 91% achieved a doubling of their platelet count to greater than or equal to 50,000 platelets/μLwith median time to response being 1 to 2 weeks depending on starting dose. The proportion of patients achieving a platelet response and median time to first response were comparable regardless of splenectomy status.
No adverse event occurred more than twice during the study. The most commonly reported were cerebrovascular accident, headache, bone marrow reticulin fibrosis, nausea, deep vein thrombosis, hemorrhage, and pulmonary embolism (2 [0.5%] patients each).
"Additional data presented at the meeting in other disease states help further elucidate the safety and efficacy profile of Nplate," said Sean E. Harper, MD, senior vice president of global development and chief medical officer at Amgen. "Collectively, these data help build upon our understanding of Nplate's treatment potential for patients with thrombocytopenia."
According to Dr Jun, Amgen will continue to monitor the safety profile of Nplate through clinical trials and post-marketing pharmacovigilance programs, as well as through other post-marketing commitments and follow-up measures.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.